Expertise in
20
conditions

Dr. Ira Jacobson

Gastroenterology
New York University
530 1st Ave, 
New York, NY 
Offers Telehealth
47 Years of Experience
Expertise in
20
conditions
New York University
530 1st Ave, 
New York, NY 

Overview

Ira Jacobson is a Gastroenterologist practicing medicine in New York, New York. He has been practicing medicine for over 47 years.

Dr. Jacobson is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Non-Alcoholic Fatty Liver Disease, Liver Transplant, and Endoscopy.

He is actively involved in clinical research, co-authoring 174 peer reviewed articles and participating in 9 clinical trials.

Graduate Year

1979

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

New York University
530 1st Ave, New York, NY 10016

Additional Areas of Focus

Dr. Jacobson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

174 Total Publications

Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey.
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: January 19, 2026
Similar Doctors
Expertise in
18
conditions
Dr. David Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David Katzka
Gastroenterology
Referral may be required

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (1.8 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist practicing medicine in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology
Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology
Referral may be required

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (3.8 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Schiano is a Gastroenterologist practicing medicine in New York, New York. Dr. Schiano is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Splenectomy.

Expertise in
23
conditions
Dr. Douglas Dieterich
Gastroenterology
Expertise in
23
conditions
Dr. Douglas Dieterich
Gastroenterology
Referral may be required

MSSM-Optical Shop

17 E 102nd St, 
New York, NY 
 (3.6 miles away)
212-241-7270
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Dieterich is a Gastroenterologist practicing medicine in New York, New York. Dr. Dieterich is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Cirrhosis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Frequently Asked Questions about Dr. Ira Jacobson

How do I make an appointment with Dr. Ira Jacobson?

You can book an appointment with Dr. Ira Jacobson by calling their office at 212-263-0474. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ira Jacobson a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ira Jacobson is classified as an Elite expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ira Jacobson specialize in?

While Dr. Ira Jacobson is a Gastroenterology, they have specific expertise in Hepatitis, Hepatitis C, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ira Jacobson participate in research or clinical trials?

Yes. Dr. Ira Jacobson has published 174 articles and abstracts on conditions like Hepatitis. You can view a list of Dr. Ira Jacobson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ira Jacobson accept my insurance?

Dr. Ira Jacobson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 212-263-0474 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacobson's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 8 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile